Page 10 - Opgen News Today

OpGen (NASDAQ:OPGN – Get Rating) had its target price decreased by Alliance Global Partners to $1.25 in a report released on Tuesday, The Fly reports. The firm currently has a “buy” rating on the medical research company’s stock. Alliance Global Partners’ price objective would indicate a potential upside of 78.57% from the company’s previous close. […]

208 patients enrolled in a prospective, randomized, controlled, multicenter, interventional trial Unyvero reduced the use of inappropriate antibiotic...

Precigen (NASDAQ:PGEN – Get Rating)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research note issued to investors on Monday, TipRanks reports. They presently have a $10.00 target price on the biotechnology company’s stock. Separately, Zacks Investment Research upgraded Precigen from a “hold” rating to a “buy” rating and set a $1.50 […]

Total Q1 2022 revenues of $0.5 millionCash position of approximately $30.7 million to reach into Q1-2023 Management conference call scheduled for May 12, 2022, at 4:30 p.m. EDT ROCKVILLE, Md.,... | May 12, 2022

Precigen (NASDAQ:PGEN – Get Rating) is scheduled to issue its quarterly earnings data after the market closes on Monday, May 9th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter. Precigen (NASDAQ:PGEN – Get Rating) last posted its earnings results on Tuesday, March 1st. The biotechnology company reported ($0.13) earnings […]

Wall Street analysts expect Precigen, Inc. (NYSE:PGEN – Get Rating) to report $20.90 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Precigen’s earnings, with the lowest sales estimate coming in at $17.30 million and the highest estimate coming in at $24.50 million. Precigen posted sales of […]

Brokerages expect that Precigen, Inc. (NYSE:PGEN – Get Rating) will announce earnings of ($0.14) per share for the current quarter, Zacks reports. Two analysts have made estimates for Precigen’s earnings, with the lowest EPS estimate coming in at ($0.15) and the highest estimate coming in at ($0.13). Precigen posted earnings of ($0.11) per share in […]

OpGen (NASDAQ:OPGN – Get Rating) released its quarterly earnings results on Tuesday. The medical research company reported ($0.35) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.16) by ($0.19), MarketWatch Earnings reports. OpGen had a negative net margin of 829.32% and a negative return on equity of 82.94%. During the same […]

PFG Advisors bought a new position in Precigen, Inc. (NASDAQ:PGEN – Get Rating) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 10,083 shares of the biotechnology company’s stock, valued at approximately $37,000. A number of other hedge funds also recently […]

Precigen, Inc. (NASDAQ:PGEN – Get Rating) saw a significant increase in short interest in the month of February. As of February 15th, there was short interest totalling 22,870,000 shares, an increase of 26.2% from the January 31st total of 18,120,000 shares. Based on an average trading volume of 1,680,000 shares, the days-to-cover ratio is presently […]